Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Investigational New Drugs

Volumn 23, Issue 4, 2005, Pages 357-361

  Chang, Susan M ^a   Wen, Patrick ^b   Cloughesy, Timothy ^c   Greenberg, Harry ^d   Schiff, David ^e   Conrad, Charles ^f   Fink, Karen ^g   Robins, H Ian ^h   De Angelis, Lisa ⁱ   Raizer, Jeffrey ⁱ   Hess, Kenneth ^f   Aldape, Ken ^f   Lamborn, Kathleen R ^a   Kuhn, John ^j   Dancey, Janet ^k   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h Unversity of Wisconsin   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

CCI 779; Chemotherapy; Efficacy; Glioblastoma multiforme; Rapamycin; Recurrent

Indexed keywords

TEMSIROLIMUS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LYMPHOCYTOPENIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; STOMATITIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUMOR GROWTH;

ADULT; AGED; ANEMIA; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; FEMALE; GLIOBLASTOMA; HUMANS; HYPERCHOLESTEROLEMIA; INFUSIONS, INTRAVENOUS; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS;

EID: 21044431575     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-1444-0     Document Type: Article

References (21)

1. Knobbe CB, Merlo A, Reifenberger G: Pten signaling in gliomas. Neuro-oncol 4: 196-211, 2002
2. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159: 359-367, 2001
3. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res 59: 1820-1824, 1999
4. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001
5. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000
6. Chen J, Fang Y: A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64: 1071-1077, 2002
7. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 103: 253-262, 2000
8. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61: 1527-1532, 2001
9. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs (in press) 22: 427-435, 2004
10. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
11. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909-918, 2004
12. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA: Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-oncol 4: 268-277, 2002
13. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279: 2737-2746, 2004
14. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746, 2003
15. Klingler-Hoffmann M, Bukczynska P, Tiganis T: Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 105: 331-339, 2003
16. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kemshead JT, Vega F, Delattre JY, Stasiecki-Steinfeld P: The epidermal growth factor receptor in glioblastoma: Genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 14: 169-174, 1995
17. Huang S, Houghton PJ: Mechanisms of resistance to rapamycins. Drug Resist Updat 4: 378-391, 2001
18. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC, Jr., Houghton PJ: Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54: 815-824, 1998
19. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62: 7291-7297, 2002
20. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141-6145, 2002
21. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB: MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19: 5406-5412, 2000